Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C] Levornidazole Disodium Phosphate Mass Balance Study in Healthy Males
NCT07906197Phase 1Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of levornidazole in bacterial infection and protozoan infection, sponsored by Yangtze River Pharmaceutical Group. Primary endpoints: Cumulative Percent Recovery of Total Radiocarbon (14C) at 10 days, Percentage of Metabolite Detected in Plasma, Urine, Feces at 10 days and 3 more. Started Oct 2024; status: completed.
02
Drugs
levornidazole
03
Conditions
bacterial infectionprotozoan infection
Beyond the preview
Go deeper on NCT07906197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906197.